Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
1998
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
2000
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
1992
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
1997
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
1998
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
1996
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
1999
Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer
1994
Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen
2003
Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
1995
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
1991
Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe
2001
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
1995
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
1993
c- erb B-2 Related Aggressiveness in Breast Cancer Is Hypoxia Inducible Factor-1α Dependent
2004
ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma
1996
The relationship between prognostic and predictive factors in the management of breast cancer
1998
HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer
2000
α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis
2003
Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
1999
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
2001
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer
2002
The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer
1997
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
1995
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
1997
Prognostic Factors in Breast Cancer
2000
EGFR Antagonists in Cancer Treatment
2008 Standout
Oncogenic kinase signalling
2001 StandoutNature
Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
1994
Growth factors and oncogenes in breast cancer
1990
Epidermal growth factor-related peptides and their receptors in human malignancies
1995 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Cancer Metastasis: Building a Framework
2006 Standout
Dissemination and growth of cancer cells in metastatic sites
2002 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Signal transduction by receptors with tyrosine kinase activity
1990 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients
1997
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
1992
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells
2003
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
The prognostic value of p53 and c-erb b-2 immunostaining is overrated for patients with lymph node negative breast carcinoma
2000
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
The molecular biology of breast cancer
1991
Parallel progression of primary tumours and metastases
2009
Emerging Biological Principles of Metastasis
2017 Standout
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Tumor angiogenesis in node-negative breast carcinomas ? relationship with epidermal growth factor receptor, estrogen receptor, and survival
1994
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Angiogenesis and Blood Vessel Invasion as Prognostic Indicators for Node-Negative Breast Cancer
2001
Generation of a functional mammary gland from a single stem cell
2006 StandoutNature
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
1991 Standout
The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients
1994
Clonal evolution in cancer
2012 StandoutNature
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
1991
Pax-2 and N-myc regulate epithelial cell proliferation and apoptosis in a positive autocrine feedback loop
2007
Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and theor relation to estradiol receptor (ER) status
1997
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer
2002
Effect of In Utero and Early-Life Conditions on Adult Health and Disease
2008 Standout
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
2006 Standout
Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.
1992
Cancer of the Ovary
2004 Standout
HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
2006
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
2006 StandoutScience
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
The landscape of metastatic progression patterns across major human cancers
2014
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
2000
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables
2001
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
1990 StandoutScience
Metabolic reprogramming and cancer progression
2020 StandoutScience
Associations between gene expressions in breast cancer and patient survival
2002
Growth Factors and Cancer
1991 StandoutScience
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
1992
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
1989 StandoutScience
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients
2005 StandoutNobel
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase
1995 StandoutScience
Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System
1999
Works of C Wright being referenced
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
1992
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
1989
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
1991
Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup
1991
Metastatic patterns of renal carcinoma: An analysis of 687 necropsies
1988
Sirenomelia, limb reduction defects, cardiovascular malformation, renal agenesis in an infant born to a diabetic mother
1997